+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
P

Actively Recruiting

Researchers are studying the safety and effectiveness of a single dose of nexiguran ziclumeran NTLA-2001 compared to a placebo in people with hereditary transthyretin amyloidosis with polyneuropathy ATTRv-PN. This phase 3, multinational, randomized, double-blind, placebo-controlled trial involves about 60 participants with this nerve disease and genetic condition affecting the peripheral nervous system. Participants will be randomly assigned to receive a single intravenous infusion of either nexiguran ziclumeran 55 mg or a placebo of normal saline. To give everyone a chance to receive the study drug, participants may switch to the other treatment group at either 12 or 18 months, depending on specific study criteria. The study is designed to compare the effects of the drug and placebo over time. During the study, participants will be monitored for nerve function using the Modified Neuropathy Impairment Score 7 mNIS7 over 18 months and blood levels of serum transthyretin at 29 days and 18 months. Quality of life, body mass index, and other health measures will also be evaluated. The study includes careful safety monitoring and will last up to 18 months with ongoing assessments to track participants nerve health and overall well-being.

Age: 18Years - 85YearsAll GendersPhase 3
14 locations
E

Actively Recruiting

Researchers are evaluating the effects of two different doses of glycopyrronium GP metered-dose inhaler MDI compared to a placebo MDI when added to budesonide and formoterol fumarate BFF MDI in children aged 4 to less than 12 years with asthma. This Phase II, multi-center, randomized, double-blind crossover study aims to assess lung function improvements with these treatments. The study includes participants who have a history of physician-diagnosed asthma and are currently on stable inhaled corticosteroids plus an additional asthma controller medication. Participants undergo a 3-week run-in period followed by three 3-week treatment periods where they receive each of the three treatments in a randomized sequence BFF MDI with GP MDI Dose A, BFF MDI with GP MDI Dose B, and BFF MDI with placebo MDI. All medications are administered via oral inhalation twice daily. After the treatment periods, there is a safety follow-up visit 12 to 16 days after the last dose of study intervention. During the study, participants attend scheduled visits for assessments including lung function tests measuring forced expiratory volume in one second FEV1 at one hour post-dose and morning pre-dose trough FEV1 at the end of treatment. Researchers monitor safety and efficacy outcomes throughout the trial, which lasts approximately 12 weeks including the run-in and treatment periods plus follow-up. The study is designed to better understand the potential benefits and safety of adding different doses of GP MDI to standard asthma treatment in pediatric patients.

Age: 4Years - 11YearsAll GendersPhase 2
44 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying GSK4527363 in a phase 1 clinical trial to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. This study includes healthy participants, people with systemic lupus erythematosus SLE, healthy individuals of Chinese and Japanese ancestry, and participants with interstitial lung disease linked to connective tissue disease CTD-ILD. The trial includes multiple groups to understand how the drug behaves across these populations. Participants receive GSK4527363, placebo matching GSK4527363, or belimumab, depending on their group. The study is divided into four parts Part A involves healthy volunteers, Part B includes participants with active SLE, Part C enrolls healthy Chinese and Japanese participants, and Part D involves those with CTD-ILD. Treatments and assessments occur over different durations, up to 52 weeks for healthy participants and up to 68 weeks for those with SLE or CTD-ILD. During the study, participants undergo medical evaluations including physical exams, lab tests, vital signs monitoring, and 12-lead ECGs. Researchers track adverse events, immune responses, drug levels in the blood, and changes in cytokine levels. Safety and tolerability are monitored closely through these measures. The total participation time varies by group, extending up to 68 weeks for some. This comprehensive monitoring helps assess the drugs effects and safety in diverse participants.

Age: 18Years - 65YearsAll GendersPhase 1
28 locations
E

Actively Recruiting

Researchers are evaluating the antiviral effects of S-337395 compared to a placebo in adults who are not hospitalized but have respiratory syncytial virus RSV infection and are at high risk of progressing to severe disease. This phase 2b study focuses on participants starting treatment within 72 hours of RSV symptom onset to assess safety, tolerability, and efficacy. The trial includes adults with specific risk factors such as advanced age and chronic lung or cardiovascular diseases. Participants are randomly assigned to one of three groups a high dose of S-337395 taken orally twice daily for up to 5 days, a low dose of S-337395 taken with the same schedule, or a matching placebo given twice daily for 5 days. The study uses a double-blind design to compare the effects of these treatments. During the study, participants will undergo nasal swabs to measure changes in RSV viral load at multiple time points days 2, 4, and 6. Researchers will also monitor RSV symptom severity, time to symptom resolution, and the presence of the virus over the first 6 days. Safety is assessed by recording any treatment-emergent adverse events up to 28 days after starting treatment. Blood samples will measure the concentration of S-337395, and participants will be observed throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 2
89 locations
E

Actively Recruiting

Researchers are studying how well and safely elafibranor works compared to a placebo in adults with Primary Sclerosing Cholangitis PSC, a rare liver disease that causes inflammation and scarring of the bile ducts. PSC can lead to serious liver damage, potentially requiring a liver transplant or causing death. This phase III study involves about 350 participants with large duct PSC. Participants will be randomly assigned to take either elafibranor 120 mg once daily or a placebo tablet daily. The study includes a screening period, a treatment period expected to last about 5 years until enough health events occur, and a post-treatment safety follow-up lasting around four weeks. The study is double-blind, meaning neither participants nor researchers know which treatment is given. Throughout the study, participants will have routine clinical assessments, lab tests, imaging evaluations, and patient-reported assessments to monitor disease progression, symptoms like pruritus and fatigue, quality of life, and safety. Researchers will measure event-free survival and monitor for adverse events and changes in vital signs and lab parameters. Participants may withdraw anytime, and the total study duration may extend over several years.

Age: 18Years - 75YearsAll GendersPhase 3
231 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease COPD who are already receiving inhaled maintenance therapy and have experienced recent COPD exacerbations. This Phase 3, multicenter, randomized, double-blind, placebo-controlled study aims to understand how tezepelumab impacts COPD outcomes compared to a placebo. Participants will receive monthly subcutaneous injections of one of two doses of tezepelumab or a matching placebo. The treatment period lasts a minimum of 52 weeks and up to 76 weeks. Following treatment, there is a 12-week safety follow-up without active treatment to monitor participants. Throughout the study, participants will be monitored regularly to assess lung function, COPD symptoms, and exacerbation rates. Researchers will collect data on lung function tests, symptom questionnaires, and exacerbation frequency up to 76 weeks. Blood samples will be taken to study drug levels and immune responses. The total participation time for each individual includes the treatment period plus the safety follow-up phase.

Age: 40Years - 80YearsAll GendersPhase 3
284 locations
E

Actively Recruiting

Researchers are investigating the safety, tolerability, and clinical activity of belantamab, alone and in combination with other drugs, in participants with multiple myeloma. The study is divided into three parts Part 1 evaluates escalating doses of belantamab in participants with refractory multiple myeloma who have had at least three prior therapies Part 2 assesses different doses of belantamab combined with belantamab mafodotin in a similar participant group Part 3 studies belantamab combined with a pomalidomide-dexamethasone standard treatment in participants who have received at least one prior therapy including lenalidomide. This phase 12 open-label trial aims to explore these treatments in participants with advanced disease. Participants receive belantamab monotherapy, belantamab with belantamab mafodotin, or belantamab with pomalidomide and dexamethasone, depending on study part. In Parts 1 and 2, treatment continues until disease progression, after which participants may opt for belantamab mafodotin alone. The study uses a sequential design with randomized allocation. Each treatment is administered as specified, and dosing adjusts according to safety and tolerability evaluations. During the study, participants undergo regular monitoring for adverse events, dose-limiting toxicities, and changes in laboratory and vital signs up to 52 months. Specific assessments include ocular event severity, response rates, and pharmacokinetic measurements. The study also tracks immunogenicity by measuring anti-drug antibodies. Researchers evaluate clinical activity through overall response rates and disease progression metrics while ensuring participant safety through ongoing evaluations and compliance monitoring.

Age: 18Years +All GendersPhase 1Phase 2
44 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.

Age: 40Years - 80YearsAll GendersPhase 3
281 locations

1-10 of 18

1